SIMCERE PHARMA (02096) announced its mid-term results, with adjusted net profit of approximately 964 million yuan, an increase of 48.7% year-on-year.

SIMCERE PHARMA (02096) announced its interim results for 2026, reporting revenues of 4.58 billion yuan, a year-on-year increase of 27.8%; revenue from innovative drugs was 3.887 billion yuan, accounting for 84.9% of total revenue, with a year-on-year growth of 34.1%. The profit attributable to the company's equity shareholders was 829 million yuan, up 37.9% year-on-year; adjusted profit attributable to the company's equity shareholders was 964 million yuan, a year-on-year increase of 48.7%. The announcement stated that the profit growth was mainly driven by the increase in revenue from innovative drugs and licensing income. The group focuses on the fields of neuroscience, oncology, autoimmunity, and anti-infection, while also proactively positioning itself in disease areas with significant clinical needs for the future, fulfilling its corporate mission of "born for patients." In its focus areas, the group has ten innovative drugs approved for market launch. As of June 30, 2026, the group has multiple products included in more than 100 guidelines and pathways published by government agencies or authoritative professional societies, and over 45 products have been included in the National Reimbursement Drug List (NRDL). The group has established overseas licensing collaborations for five independently developed innovative drugs with leading international pharmaceutical companies such as AbbVie, Boehringer Ingelheim, and Ipsen, with a total transaction amount exceeding $4.6 billion. This fully reflects global partners' recognition of the group's independent research and development capabilities, the quality of its innovative pipeline, and the global market potential of its products, laying a foundation for the global development and value realization of innovative achievements and becoming an important driving force for the group's sustained growth. The group continues to strengthen its capacity for innovative drug development, with research and innovation centers set up in Shanghai, Nanjing, Beijing, Boston, and Hong Kong. It has also established a national key laboratory for research and development of neurology and oncology drugs. The group's research and development system covers the entire process of drug discovery, preclinical development, clinical trials, and registration submissions, and possesses leading platforms in protein engineering, multi-antibody/TCE, ADC, messenger RNA (mRNA), AI-assisted molecular generation, and protein degradation. As of June 30, 2026, the group has approximately 1,000 researchers (including around 214 PhD holders and approximately 520 master's degree holders).